SKShiyam Kumar

Shiyam Kumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shiyam Kumar has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Beliefs and Perceptions About Cancer Diagnosis and Treatment-Seeking and Decision-Making Behaviors Among Omani Patients with Cancer: A Single-Center Study

    by Shiyam Kumar, Muna Al-Balushi, Philomena Charlotte Dsouza, Khalid Al-Baimani, Ikram A. Burney, Mansour Al-Moundhri

    A cancer diagnosis is associated with anxiety and psychological distress. Cultural and societal factors greatly affect the complex process of coping mechanisms and decision making. Omani patients receiving cancer treatment at Sultan Qaboos University Hospital in Oman were interviewed about their perceptions regarding cancer, treatment, outcome, and decision making. Out of a total of 360 approached, 216 patients consented. The median age was 42 years. The results showed that 60.6% of patients considered cancer diagnosis as a test from God, 13.9% considered it as a result of an evil eye, 40% believed prayers treat cancer. Fifty-six percent of participants wanted to make treatment decisions themselves, while 2.3% preferred their family to make decisions. Our findings suggest that perceptions about cancer in Oman are specific and are associated with religion and sociocultural background.


  • Open Access

    Complications and Management of Totally Implantable Central Venous Access Ports in Cancer Patients at a University Hospital in Oman

    by Philomena C D'SOuza, Shiyam Kumar, Annupam Kakaria, Rashid Al-Sukaiti, Khalid Al-Baimani, Rana S Hamid, Alok K Mittal, Muna Al-Balushi, Ikram A Burney, Mansour S Al-Moundhri

    Objectives: Totally implantable central venous access ports (port-a-caths) are increasingly used for the safe administration of chemotherapy; however, their use is associated with complications. This study reviews patterns of complications, reasons for premature removal and the duration of the use of port-a-caths in patients receiving cancer treatment at Sultan Qaboos University Hospital (SQUH) and compares the infection rate with the literature and the researchers’ experiences. Methods: This retrospective follow-up study included patients who had received cancer treatment through a port-a-cath and were admitted to SQUH between January 2007 and April 2019. Demographic features, underlying diagnosis, clinical stage, treatment, duration of use and the cause of premature removal of the port-a-cath were recorded. Results: A total of 516 port-a-caths were inserted in 482 cancer patients. The majority of devices were implanted by interventional radiologists (n = 459; 89.0%) and the right internal jugular vein was most frequently accessed (n = 396; 76.7%). The mean indwelling time of a port-a-cath was 288 days (range: 3–1,872 days) for patients with complications and 550 days (range: 7–3,123 days) for patients without complications. Port-a-cath-related infection was the main complication (n = 63; 12.2%). Patient age, gender, treatment intent, underlying diagnosis, clinical stage, chemotherapy regimen, number of treatment courses, operator implanting the port, the type of micro-organism isolated from the port-a-cath and body mass index were significant factors affecting catheter indwelling time (P <0.05). On multivariate analysis, however, none of the factors was found to be significant. Conclusion: Infection was the most common complication necessitating port-a-cath removal. The infection rate was much lower than the researchers’ previous experience and compares favorably with several published reports.


  • Open Access

    Clinicopathological features, treatment and outcome of Omani patients with localised prostate cancer

    by Shiyam Kumar, Ikram A. Burney, Namrata Satyapal, Joseph Kunju, Mohamed Salim Al-Marhoon, Khurrum Mutahir Siddiqui

    To report the outcomes of Omani men diagnosed with localised prostate cancer (PCa), as PCa incidence is increasing in developing countries and there are scarce data regarding clinicopathological fe...


  • Open Access

    Outcome of Omani Women with Breast Cancer-associated Brain Metastases Experience from a University Hospital

    by Khawaja F. Zahid, Shiyam Kumar, Khalid Al-Bimani, Tanweer Ahmed, Adil Al-Ajmi, Ikram A. Burney, Mansour Al-Moundhri

    Breast cancer (BC) is the leading cancer among women. Almost 20% of patients develop brain metastases (BM) and die shortly afterward. There is a dearth of data on the survival outcome of BC patients with BM from the Arab world. Consecutive women diagnosed with BC who developed radiologically-confirmed BM during their illness were identified through the hospital's electronic patient's records. Clinicopathological features and treatment outcomes were recorded. Survival was calculated using the Kaplan-Meier method, and factors affecting survival were studied using log-rank analysis. Between January 2003 and June 2015, a total of 692 patients were treated for BC at our institute. Forty-eight (6.9%) developed BM. The median age at the diagnosis of BM was 45.2 years. More than half of cohort (54.2%) had HER2 positive disease, while 27.1% had the triple-negative disease. The median time interval between the diagnosis of BC and the development of BM was 21 months, and median survival after development of brain disease was seven months. On univariate analysis, pathological grade, previous systemic treatment, brain as the first site of metastases, brain as the only site of metastases, treatment of BM, systemic treatment after BM, and diagnosis-specific graded prognostic assessment (DS-GPA) score significantly affected survival. On multivariate Cox regression analysis, the brain as the first site of metastases, treatment for brain disease, treatment type, and DS-GPA score significantly affected survival post-BM. Our data indicate that Omani women are diagnosed with BC at a younger age, develop BM earlier, and carry a poor outcome.


  • Open Access

    Relapse of herpes simplex encephalitis in a patient with metastatic small cell lung cancer following scalp sparing whole brain radiotherapy

    by A. Balkhair, A. Al Wahaibi, S. Raniga, M. Al Amin, F. Ba Alawi, M. El-Tigani, S. Kumar


  • Open Access

    Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience

    by Shiyam Kumar, Muhammad Furrukh, Khalid Al-Baimani, Adil Al-Ajmi, Ikram A. Burney, Mansour S. Al-Moundhri

    Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience


  • Open Access

    Trends and Outcomes of Non-Small-Cell Lung Cancer in Omani Patients: Experience at a university hospital

    by Muhammad Furrukh, Shiyam Kumar, Khawaja F. Zahid, Hanan S. Al-Shamly, Zainab A. Al-Jabri, Ikram A. Burney, Mansour S. Al-Moundhri

    Trends and Outcomes of Non-Small-Cell Lung Cancer in Omani Patients: Experience at a university hospital


  • Open Access

    Calpain-1 Expression in Triple-Negative Breast Cancer: A Potential Prognostic Factor Independent of the Proliferative/Apoptotic Index

    by Shadia M. Al-Bahlani, Ruqaya M. Al-Rashdi, Shiyam Kumar, Shadia S. Al-Sinawi, Maiya A. Al-Bahri, Asem A. Shalaby

    Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer in which calpain system plays an important role in its cellular processes including apoptosis and proliferation. Although such roles have been assessed in tumor pathogenesis, the correlation of its expression to the proliferating/apoptotic index has not been studied yet. Immunohistochemical staining of calpain-1 was performed on paraffin-embedded tissues to correlate its expression with clinicopathological variables and outcome. The proliferation activity was determined by calculating the percentage of cells expressing the Ki-67 antigen. The apoptotic index was assessed morphologically and biochemically using Haematoxylin & Eosin method and Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling assay, respectively. Calpain-1 was significantly expressed in TNBC tissues varying from low to high with a significant correlation to lymph node status but not with the other clinicopathological variables, suggesting its role as a prognostic factor. In addition, a positive correlation was found between both apoptotic counts assays (P<0.001, r=0.547) as well as with proliferation (P=0.045). Calpain-1 expression had no significant correlation with either proliferation (P=0.29) or apoptotic indices (P=0.071 and P=0.100). Determining calpain-1 expression may provide relevant prognostic value for TNBC cancer patients.


  • Presenting features, treatment patterns and outcomes of patients with breast cancer in Pakistan: Experience at a university hospital

    by S Kumar, Aj Shaikh, Ya Rashid, N Masood, Atv Mohammed, Uz Malik, G Haider, N Niamutullah, S Khan

    Background: Breast cancer is the most common cancer in Pakistani women. We report the presenting features, treatment patterns and survival of breast cancer from a University Hospital in Southern Pakistan and compare the data with international population based studies. Materials and Methods: Medical records of patients diagnosed to have breast cancer between January 1999 and November 2008 were reviewed retrospectively. Results: A total of 845 patients were identified. Median age of diagnosis was 48 years (range 18-92). Clinical stage was as follows: Stage I 9.9%; Stage II 48.5%; Stage III 26.2%; Stage IV 13.8%; data not available 1.5%. Approximately, half (51.6%) were estrogen receptor (ER) positive and 17.5% over-expressed Her2/neu. Nearly 23% patients received neo-adjuvant chemotherapy while 68.9% received adjuvant chemotherapy. Anthracycline based treatment was the most common treatment until 2003 while later on, patients also received taxanes and trastuzumab based therapy. Age, stage, tumor size, lymph node status, tumor grade, ER status, treatment with hormonal therapy and radiation were the major predictive factors for overall survival (OS). We report an impressive 5 year OS of 75%, stage specific survival was 100%, 88% and 58% for Stages I, II and III respectively. Conclusion: The majority of patients present at a younger age and with locally advanced disease. However, short term follow-up reveals that the outcomes are comparable with the published literature from developed countries. Long-term follow-up and inclusion of data from population-based registries are required for accurate comparison.